Neu REFIX β-glucan reduces muscle fibrosis in Duchenne muscular dystrophy MDX mice, in joint research with Dr. Yoshitsugu Aoki, NCNP, Tokyo, Japan.
Skeletal muscle fibrosis which leads to locomotor dysfunction in Duchenne Muscular Dystrophy (DMD) could be significantly reduced by oral consumption of Neu-REFIX beta 1,3-1,6 glucans alone for 45 days without any other drugs, in MDX mice model of DMD. This research was undertaken jointly with the team of Dr Yoshitsugu Aoki, Head, Dept. of Molecular Therapy, National Center for Neurology and Psychiatry (NCNP), Tokyo, Japan, a pioneer in developing solutions to DMD such as exon skipping therapy. The findings published in Scientific Reports, a publication by Nature portfolio also reported a reduction in muscle inflammation, which precedes fibrosis and muscle dysfunction, leading gradually to respiratory muscle failure followed by lung dysfunction, cardiac fibrosis, heart failure and premature death.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231016033169/en/
An illustrative summary of the research outcome with Neu REFIX Beta glucan presents, several “Firsts” to its credit; (1) Oral consumption of a food supplement alone, without any other drugs, reducing skeletal muscle fibrosis in MDX mice, (2) In clinical studies, increase in plasma dystrophin which is considered of relevance to correction of vascular smooth muscle pathology, (3) Clinically evident beneficial reconstitution of gut microbiome in patients with DMD in a 45- days clinical study, (4) Reduction of myocardial fibrosis with neu REFIX alone in MDX mice, (5) Slowing down the progress of DMD pathology evident by 6MWT, NSAA and MRC in a six-month clinical study when Neu REFIX was consumed along with standard of care medication; Neu REFIX 1,3-1,6 Beta glucan is a food supplement without any therapeutic claims; Not a drug or remedy to any illness. Research findings not to be construed as medical advice. Neu REFIX doesn’t contain any of the commonly notified 28 allergens. (Graphic: Business Wire)
This study followed an earlier clinical trial involving 27 patients in two groups in which safety along with reduction of inflammation and fibrosis and increase in plasma dystrophin were confirmed in those who consumed the same neu REFIX Beta-glucans along with standard of care medications, compared to the control group who took only the standard of care medications. An important break-through in this animal study is that the treatment-arm group MDX mice consumed only the Neu-REFIX Beta glucans without any drugs, unlike the clinical study. Currently, for DMD there are no definitive and efficacious remedies available. Exon skipping therapy is available only to less than 30% of the patients with specific exon deletions and gene therapy may not be applicable to patients in the advanced stages of DMD. Going by our clinical experience, Neu-REFIX β-glucans are worth validating clinically for longer duration, both as a stand-alone option and also as an adjuvant to standard of care medications, in different sets of appropriate age groups of patients, opined Dr Raghavan, who has recently completed another clinical study of six-months duration wherein Neu-REFIX yielded improvement in 6MWT, NSAA & MRC.
With additional experiments in MDX mice underway, as more data evolves, that may be value adding to recommend Neu REFIX β-glucan to DMD patients, said Dr Yoshitsugu Aoki. Reduction of myocardial fibrosis in MDX mice and beneficial reconstitution of gut microbiome in clinical studies give us a hope that this allergen-free orally consumable and safe food supplement could become a worthy adjuvant to disease modifying treatments in DMD, said researchers who presented the data in World Muscle Society WMS 2023 and World Congress of Neurology WCN 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Samuel JK Abraham
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo’s New All-in-One, AI-Powered Solution with Microsoft Simplifies Security and Removes the Need for Multiple Vendors6.12.2023 12:00:00 CET | Press release
Lenovo and Microsoft are working together to help organizations operate more securely across their devices, users, apps, data, networks, and cloud services through a subscription-based Cyber Resiliency as a Service (CRaaS) offering. The offering enables Lenovo to build next generation security solutions and services directly on Microsoft technology including Microsoft Azure, Microsoft Defender, and Microsoft Sentinel to simplify security deployments and enhance security posture to help prevent, detect, and recover from potentially disruptive cyber events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206935072/en/ Top Challenges Faced by CIOs (Graphic: Business Wire) CRaaS addresses growing security challenges for businesses of all sizes. Lenovo’s global annual survey of CIOs found that data privacy/security (68%) and cybersecurity/ransomware (68%) are the top two challenges businesses find most difficult to address.1 Wi
International Sustainable Forestry Coalition Welcomes New Member, Suzano6.12.2023 11:37:00 CET | Press release
In September a group of leading global sustainable forestry companies launched the International Sustainable Forestry Coalition (ISFC), to enable the sector to positively contribute to global policy processes focused on the transition from a fossil-based economy to a circular bioeconomy. Today the ISFC is delighted to announce that Suzano, one of the world’s major forestry sector companies, has become a member. Suzano, headquartered in Brazil, is a globally respected forestry sector leader. With almost a hundred years in operation, the company manages extensive sustainable timber plantation estates and forest conservation areas, and creates a vast range of fibre-based products. One out of every three tissue products used in the world today will have come from Suzano’s operations. Convening Chair of the ISFC Dr. David Brand said, “With the inclusion of Suzano in the ISFC, the group represents more than 12.6 million hectares (31 million acres) of forests for conservation and production i
Forrester: European Retail Sales To Reach €2.7 Trillion By 20286.12.2023 11:00:00 CET | Press release
Forrester (Nasdaq: FORR) forecasts that total retail sales of Europe-5 countries (France, Germany, Italy, Spain, and the UK) will increase from €2.3 trillion in 2023 to reach €2.7 trillion in 2028 at a 2.9% compound annual growth rate (CAGR). Forrester’s recently released report, Europe-5 Online Retail Forecast, 2023 To 2028, estimates total retail sales, online retail sales, and online retail penetration across 22 product categories, including fashion, homeware, food and drink, consumer electronics, and media, for each of the Europe-5 economies. Germany holds the largest share of the retail market among these five countries, followed (in order) by the UK and France. In 2022, offline retail growth outpaced online retail growth for the first time as more consumers shopped in stores, and this momentum continued into 2023, but the fundamental growth drivers of online retail such as greater product selection, round-the-clock availability, and competitive pricing remain strong. As a result,
Kaneka Acquires Japan Medical Device Technology6.12.2023 10:40:00 CET | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206372197/en/ Stent before expansion (Photo: Business Wire) Kaneka manufactures and sells endovascular catheters, which are devices used in the treatment of cardiac, peripheral vascular, and cerebrovascular diseases. In particular, stenting*1 for the treatment of coronary artery diseases such as atherosclerosis has a market worth 30 billion yen in Japan, and Kaneka is aiming to expand its business in this area. JMDT has high technological capabilities in the research and development of coronary stents and is one of the lead
CommBox launches Era AI to enable customer service to be intelligently automated and CX costs to be cut by 40%6.12.2023 10:00:00 CET | Press release
Today CommBox, the pioneer in AI-powered customer communications, is launching its new generative AI solution. Designed for medium to large businesses across a range of industries including healthcare, banking, retail, telecommunications and insurance, Era AI is based on a winning combination of both proprietary technology developed by CommBox and commercial large language models. Era AI’s functionality scans enterprise knowledge sources and, in just seconds, provides customers with accurate, highly personalised information through the digital messaging channel of their choice. Era AI delivers customer service automation, reduces costs for organisations, and dramatically increases the speed and accuracy of enquiry handling. It does this all while increasing customer satisfaction, with CommBox customers seeing a 92% customer satisfaction rate on average. Central to this is Era AI’s ability to analyse a brand’s entire resource base, such as support articles, help and knowledge centres, a